Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults

Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults

The Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a statistical safety signal for Guillain-Barré syndrome (GB...

Full description

Bibliographic Details
Main Authors: Cara B. Janusz, Tara C. Anderson, Andrew J. Leidner, Grace M. Lee, Kathleen Dooling, Lisa A. Prosser
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster vaccination
recombinant zoster vaccine
shingrix
adult vaccination
risk-benefit
vaccine safety
Online Access:http://dx.doi.org/10.1080/21645515.2022.2060668

Internet

http://dx.doi.org/10.1080/21645515.2022.2060668

Similar Items